Source-grounded facts extracted from BRISTOL MYERS SQUIBB CO's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BRISTOL MYERS SQUIBB CO reported the first quarter of 2026 results: revenue $11,489, EPS $1.31. Guidance reaffirmed.
“progress into meaningful outcomes for patients and shareholders." First Quarter Results $ in millions, except per share amounts 2026 2025 Change Change Excl. FX** Total Revenues $11,489 $11,201 3 % 1 % Earnings/(Loss) Per Share - GAAP* 1.31 1.20 9 % N/A Earnings/(Loss) Per Share - Non-GAAP* 1.58 1.80 (12) % N/A Acquired IPRD Charges and Licensing Income Net”
Sandra Leung retired as Executive Vice President, General Counsel at BRISTOL MYERS SQUIBB CO.
“On February 14 , 2025, Sandra Leung notified Bristol-Myers Squibb Company (the “Company”) of her intention to retire from her position as Executive Vice President, General Counsel in 2025.”
Michael R. McMullen was elected as Director at BRISTOL MYERS SQUIBB CO.
“On June 18, 2024, the Board of Directors (the “Board”) of Bristol-Myers Squibb Company (the “Company”) elected Mr. Michael R. McMullen to serve as a member of the Board, effective July 1, 2024.”
BRISTOL MYERS SQUIBB CO shareholders rejected Shareholder proposal on Executive Retention of Significant Stock at the 2024-05-07 meeting.
“Item 6. The shareholder proposal on Executive Retention of Significant Stock was not approved based upon the following votes: For Against Abstain Broker Non-Vote 573,933,418 908,578,794 7,210,637 266,572,438”
BRISTOL MYERS SQUIBB CO shareholders rejected Shareholder proposal on adoption of Board policy that Chairperson be independent director at the 2024-05-07 meeting.
“Item 5. The shareholder proposal on the adoption of a Board policy that the Chairperson of the Board be an independent director was not approved based upon the following votes: For Against Abstain Broker Non-Vote 472,322,369 1,011,335,836 6,064,644 266,572,438”
BRISTOL MYERS SQUIBB CO shareholders approved Approval of amendment to Amended and Restated Certificate of Incorporation to eliminate or limit monetary liability of specified executive officers for breach of duty of care at the 2024-05-07 meeting.
“Item 4. The management proposal to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to provide for the elimination or limitation of monetary liability of specified executive officers of the Company for breach of the duty of care was approved by a majority of the outstanding shares (the required voting standard for this proposal) based upon the following votes: For Against Abstain Broker Non-Vote 1,256,661,971 227,187,844 5,873,034 266,572,438”
BRISTOL MYERS SQUIBB CO shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for 2024 at the 2024-05-07 meeting.
“Item 3. The appointment of Deloitte & Touche LLP as independent registered public accounting firm for the Company for 2024 was ratified based upon the following votes: For Against Abstain 1,706,412,572 45,388,759 4,493,956”
BRISTOL MYERS SQUIBB CO shareholders approved Advisory vote to approve compensation of named executive officers at the 2024-05-07 meeting.
“Item 2. The management proposal on the advisory vote to approve the compensation of our named executive officers was approved based upon the following votes: For Against Abstain Broker Non-Vote 1,398,917,461 82,961,647 7,843,741 266,572,438”
BRISTOL MYERS SQUIBB CO shareholders approved Election of 10 director nominees at the 2024-05-07 meeting.
“Item 1. The shareholders elected each of the Company’s 10 nominees to serve as directors on the Board of Directors (the “Board”) of the Company until the 2025 Annual Meeting based upon the following votes: For Against Abstain Broker Non-Vote Peter J. Arduini 1,383,602,367 102,481,962 3,638,520 266,572,438 Deepak L. Bhatt, M.D., M.P.H. 1,476,515,465 9,708,358 3,499,026 266,572,438 Christopher S. Boerner, Ph.D. 1,384,853,031 94,529,721 10,340,097 266,572,438 Julia A. Haller, M.D. 1,476,206,049 10,127,433 3,389,367 266,572,438 Manuel Hidalgo Medina, M.D., Ph.D. 1,476,575,465 9,619,439 3,527,945 266,572,438 Paula A. Price 1,454,211,368 32,151,447 3,360,034 266,572,438 Derica W. Rice 1,434,633,116 51,626,067 3,463,666 266,572,438 Theodore R. Samuels 1,424,280,995 61,627,002 3,814,852 266,572,438 Karen H. Vousden, Ph.D. 1,453,794,945 32,477,142 3,450,762 266,572,438 Phyllis R. Yale 1,466,891,645 19,409,908 3,421,296 266,572,438”
BRISTOL MYERS SQUIBB CO reported the first quarter of 2024 results: revenue $11,865, EPS (5.89).
“get the most promising medicines to patients as quickly as possible." 1 First Quarter $ in millions, except per share amounts 2024 2023 Change Change Excl. F/X** Total Revenues $11,865 $11,337 5 % 6 % (Loss)/Earnings Per Share — GAAP* (5.89) 1.07 N/A N/A (Loss)/Earnings Per Share — Non-GAAP* ** (4.40) 2.05 N/A N/A Acquired IPRD charge and Licensing Income Net”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.